CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 122 enrolled
Drug / intervention
Teriparatide +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01473589
NCT01473589Phase 3Completed
CompareCT.gov

Effect of Teriparatide on Femoral Neck Fracture Healing

Eli Lilly and Company·interventional·Posted Nov 17, 2011·Updated Apr 16, 2015

In Brief

A Phase 3 clinical trial evaluating Teriparatide, Placebo, and 2 other interventions for Femur Neck Fracture. Completed, enrolled 122 participants across 92 sites in 19 countries.

Detailed Summary

The purpose of this study is to see whether teriparatide, given for 6 months versus placebo, will improve the healing of hip (femoral neck) fractures that are repaired during surgery using certain types of orthopedic screws. The study will enroll men and postmenopausal women at least 50 years of age with a recent hip (femoral neck) fracture caused by low-trauma (for example, fall from standing height or less).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFemur Neck Fracture
CountriesAustralia, Canada, Denmark, Estonia, Finland, Hong Kong, India, Israel, Japan, Latvia, Lithuania, New Zealand, Norway, Puerto Rico, South Korea, Spain, Sweden, Taiwan, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 17, 2011
Enrollment StartFeb 1, 2012
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.6 years ago

Interventions

Teriparatidedrug

Administered by SC injection

Placebodrug

Administered by SC injection

Calcium supplementationdietary

Administered orally

Vitamin D supplementationdietary

Administered orally